About Decipher
Decipher is a Healthcare company based in San Diego (United States) founded in 2008, and was acquired by Veracyte in February 2021. Genomic test solutions for cancer diagnosis are developed. It operates on a HealthTech model. Its chief executive, as recorded, is Tina S Nova. Decipher offers products and services including Decipher Prostate and Decipher Bladder. Its focus areas include Biotechnology and Genomic Testing. Its legal entity is Veracyte, Inc. Its competitors include Guardant Health, GRAIL and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Genomic testing solutions are developed by Veracyte, Inc. under the Decipher brand for urologic cancers, specifically prostate and bladder cancer. Actionable insights are offered to physicians and patients through Decipher Prostate and Decipher Bladder tests to support informed treatment decisions. The focus is placed on evidence-driven science to improve outcomes in the cancer care journey. Research and development in this sector are advanced through tools like Decipher GRID, contributing to personalized care in healthcare.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website decipherbio.com
- Social LinkedIn X
- Acquired by Veracyte (Feb 2021)
- Legal Name Veracyte, Inc.
Products & Services of Decipher
Decipher offers a comprehensive portfolio of products and services, including Decipher Prostate and Decipher Bladder.
Genomic test for prostate cancer treatment decision-making support.
Genomic subtyping tool for bladder cancer treatment decisions.
Investors in Decipher
Decipher has secured backing from 1 investor. Prominent investors backing the company include Veracyte.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Genomics-based diagnostic tests for cancer are developed. | 2008 | veracyte.com | San Francisco, United States |
Investor details for Decipher
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Decipher
1 people are tracked at Decipher (1 in leadership).
| Name | Role | Group |
|---|---|---|
Tina S Nova | CEO | Leadership |
Complete people profiles for Decipher
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Decipher
2 dated milestones of Decipher across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Decipher is founded.
- Exit Acquired by Veracyte.
Competitors of Decipher
Decipher has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of Decipher
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Decipher
The website of Decipher (decipherbio.com) receives about 6.1K visits a month.
- Monthly visits6.1K
▼ 23.8% vs previous month
Websites whose visitors overlap most with Decipher. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pcmarkers.com | 100% | #4,274,700 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Decipher (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Decipher
Complete news archive for Decipher
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Decipher
Decipher was founded in 2008.
Decipher is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Tina S Nova is the CEO of Decipher, as recorded in our data.
Genomic testing solutions are developed by Veracyte, Inc. under the Decipher brand for urologic cancers, specifically prostate and bladder cancer. Actionable insights are offered to physicians and patients through Decipher Prostate and Decipher Bladder tests to support informed treatment decisions. The focus is placed on evidence-driven science to improve outcomes in the cancer care journey. Research and development in this sector are advanced through tools like Decipher GRID, contributing to personalized care in healthcare.
Decipher's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Decipher offers Decipher Prostate and Decipher Bladder.
Decipher has 1 investor. Key investors include Veracyte.
Decipher operates through Veracyte, Inc..
Yes. Decipher was acquired by Veracyte in February 2021.